The results showed that GRg3 was able to reduce the expression of ZFP91 in pancreatic cancer cells in a dose-dependent manner, improve ZFP91-induced tumor resistance and enhance the drug sensitivity and antitumor efficacy of GEM (10). This evidence concerns the gene ZFP91 and pancreatic neoplasm.